Sidransky directs two NIH clinical protocols, one evaluating patients with lysososmal storage disorders and the second prospectively studying patients and relatives with parkinsonism who carry mutations in GBA. The Sidransky group uses a translational approach, integrating both clinical and basic sciences.[1]